We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
In vitro and in vivo anti-Toxoplasma activities of HDAC inhibitor Panobinostat on experimental acute ocular toxoplasmosis.
- Authors
Yu Zhang; Qingqing Zhang; Haiming Li; Hua Cong; Yi Qu
- Abstract
Ocular toxoplasmosis (OT) is retinochoroiditis caused by Toxoplasma gondii infection, which poses a huge threat to vision. However, most traditional oral drugs for this disease have multiple side effects and have difficulty crossing the blood-retinal barrier, so the new alternative strategy is required to be developed urgently. Histone deacetylases (HDAC) inhibitors, initially applied to cancer, have attracted considerable attention as potential anti-Toxoplasma gondii drugs. Here, the efficacy of a novel HDAC inhibitor, Panobinostat (LBH589), against T. gondii has been investigated. In vitro, LBH589 inhibited the proliferation and activity of T. gondii in a dose-dependent manner with low toxicity to retinal pigment epithelial (RPE) cells. In vivo, optical coherence tomography (OCT) examination and histopathological studies showed that the inflammatory cell infiltration and the damage to retinal architecture were drastically reduced in C57BL/6 mice upon treatment with intravitreal injection of LBH589. Furthermore, we have found the mRNA expression levels of inflammatory cytokines were significantly decreased in LBH589-treated group. Collectively, our study demonstrates that LBH589 holds great promise as a preclinical candidate for control and cure of ocular toxoplasmosis.
- Subjects
HISTONE deacetylase inhibitors; TOXOPLASMOSIS; OPTICAL coherence tomography; INTRAVITREAL injections; LABORATORY mice
- Publication
Frontiers in Cellular & Infection Microbiology, 2022, Vol 12, p1
- ISSN
2235-2988
- Publication type
Article
- DOI
10.3389/fcimb.2022.1002817